Compare emicizumab and factor VIII for joint and bone health
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and age 16 or older
- You have severe hemophilia A, with factor VIII under 1%
- You are already on factor VIII or emicizumab, and you plan to stay on your current regimen for about 3 years
- You can do bone/joint testing and possibly blood tests (MSKUS and DEXA, plus blood samples if needed)
- You can attend a baseline visit and follow-up visits every 3 years, plus phone check-ins every 3 months
- You are able and willing to sign consent paperwork
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study compares how two different hemophilia A treatments affect bone strength and health in men over time. Researchers will track bone density and collect blood samples to understand whether one treatment protects bones better than the other.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.